Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group

Research output: Contribution to journal › Meeting abstract › Contributed › peer-review

Contributors

  • F. Lordick - (Author)
  • S. Lorenzen - (Author)
  • S. Hegewisch-Becker - (Author)
  • G. Folprecht - , Department of Internal Medicine I (Author)
  • E. Woell - (Author)
  • T. Decker - (Author)
  • E. Endlicher - (Author)
  • N. Roethling - (Author)
  • F. Fend - (Author)
  • C. Peschel - (Author)

Details

Original languageEnglish
Number of pages1
JournalJournal of clinical oncology
Volume25
Issue number18
Publication statusPublished - 20 Jun 2007
Peer-reviewedYes

External IDs

ORCID /0000-0002-9321-9911/work/142252043

Keywords

Sustainable Development Goals